Key result
Semaglutide reduces BMI by ~16 percentage points vs placebo in children with obesity.
Why the study?
Does once-weekly subcutaneous semaglutide reduce body-mass index (BMI) at week 68 compared to placebo in children 6 to <12 years of age with obesity?
RCT (n=167)
Double-blind
2:1 ratio
Does once-weekly subcutaneous semaglutide reduce body-mass index (BMI) at week 68 compared to placebo in children 6 to <12 years of age with obesity?
In children aged 6 to <12 years with obesity, once-weekly subcutaneous semaglutide for 68 weeks resulted in a significantly greater reduction in BMI compared to placebo (-13.5% vs 2.7%).
Answers are grounded in this paper and cite their sources.
Semaglutide plus lifestyle intervention reduces BMI in children aged 6–11 with obesity; extends RCT evidence to younger ages and supports expanded approval.
BACKGROUND: Childhood obesity is a chronic, neurometabolic disease with limited options for medical treatments that are efficacious and durable. Once-weekly subcutaneous semaglutide is approved for the treatment of obesity in adolescents and adults, but data for its use in young children are lacking. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving children (6 to <12 years of age) with obesity. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide or placebo for a period of 104 weeks, after which participants stopped taking semaglutide or placebo for a 7-week washout period. Both groups received counseling for lifestyle modification. The primary end point was the percent change in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) from baseline to week 68. The confirmatory secondary end point was a reduction in BMI category at week 68. RESULTS: Among 167 children who underwent randomization, 112 were assigned to receive semaglutide and 55 to receive placebo. At week 68, the mean percent change in BMI was -13.5% with semaglutide and 2.7% with placebo (estimated between-group difference, -16.2 percentage points; 95% confidence interval [CI], -19.4 to -12.9; P<0.001). The percent change in BMI at week 104 was -9.4% with semaglutide and 8.4% with placebo (between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3). At week 68, a reduction in BMI category had occurred in 79% of the participants in the semaglutide group and in 23% of those in the placebo group (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001), with the BMI below the threshold for obesity (the 95th percentile for age and sex) in 38% of the participants who received semaglutide and in 2% of those who received placebo. Adverse events occurred in 96% of the participants receiving semaglutide and in 93% of those receiving placebo. Gastrointestinal adverse events were the most common, occurred more frequently with semaglutide than with placebo, and led to discontinuation in 1 participant in the semaglutide group. CONCLUSIONS: Among children (6 to <12 years of age) with obesity, treatment with semaglutide for 68 weeks resulted in a significantly greater mean percent reduction in BMI than placebo. (Funded by Novo Nordisk; STEP Young ClinicalTrials.gov number, NCT05726227.).
No takes yet. Share an insight, caveat, or question.
Jastreboff et al. (2026) conducted an RCT in Childhood obesity (n=167). Semaglutide vs. Placebo plus counseling for lifestyle modification was evaluated on Percent change in body-mass index (BMI) from baseline to week 68 (MD -16.2 percentage points, 95% CI -19.4 to -12.9, p=<0.001). Once-weekly subcutaneous semaglutide reduced BMI at week 68 vs placebo in children aged 6 to <12 years with obesity.
Synapse has enriched 10 related papers. Consider them for comparative context: